Evaluate the Effects of Renal Impairment on the Pharmacokinetics and Pharmacodynamics

NCT ID: NCT05323136

Last Updated: 2023-01-26

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1
• Total Enrollment: 2 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-04-15
• Study Completion Date: 2022-06-29

Brief Summary

The study is a multicenter, Phase 1, open-label, sequential, adaptive, single dose, PK/PD study in subjects with moderate and severe RI and healthy volunteers (HV).

Detailed Description

Because MT1002 for Injection is being developed for use as an anticoagulant and antiplatelet in patients with ACS and in patients undergoing PCI, these patients may have impaired RF, and it is important to evaluate whether exposure-response or exposure-safety relationship will be altered in RI. In addition, according to the FDA recommendations, a dedicated RI study including severe RI must be conducted.

The study will be performed in 2 sequences, with interim safety, tolerability, PK, and PD review between both sequences:

Conditions

ACS - Acute Coronary Syndrome

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Renal impairment

moderate and severe Renal impairment subjects

Group Type: EXPERIMENTAL

MT1002 for Injection

Intervention Type: DRUG

single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.

Healthy control

Healthy control subjects with normal renal function

Group Type: EXPERIMENTAL

MT1002 for Injection

Intervention Type: DRUG

single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.

Interventions

MT1002 for Injection

single dose: 0.90 mg/kg initial loading dose (bolus intravenous injection) over 5 minutes + 1.8 mg/kg/hour (infusion) for 4 hours.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Male or female, non-smoker, ≥ 18 and ≤ 80 years of age, with BMI > 18.0 and < 40.0 kg/m2 and body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females.

2. Female subjects (except for post-menopausal women) must agree to use an adequate method of contraception during the study and for 90 days following the end-of-study visit.

3. Female subjects of non-childbearing potential must be:

1. Post-menopausal or

2. Surgically sterile.

4. Male subjects who are not vasectomized for at least 3 months prior to dosing, and who are sexually active with a female partner of childbearing potential must be willing to use one of the following acceptable contraceptive methods from dosing dose and for 90 days after dosing.

5. Able to understand the study procedures and provide signed informed consent to participate in the study.

6. Have a RF ≥ 90 mL/min (using the MDRD4 Equation).

7. Healthy as defined by:

1. The absence of clinically significant illness and surgery within 4 weeks prior to study drug administration.

2. The absence of clinically significant history of neurological, endocrine, cardiovascular, cerebrovascular, respiratory, hematological, immunological, psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.

8. Matched to subjects with RI (moderate or severe) according to gender, age (± 10 years), and BMI (± 15%) to the extent possible.

9. Have a diagnosis of RI that has been stable, without significant change in overall disease status in the last 3 months prior to screening as determined by the PI.

10. Have a RF expressed in mL/min (using MDRD4 Equation) within the range of at screening:

1. 30 to 59 mL/min (Moderate RI, Group 1);

2. < 30 mL/min (Severe RI, Group 3) not requiring dialysis.

Exclusion Criteria

1. Positive pregnancy test at screening or Baseline (Day -1), lactating female subject, or planned to become pregnant during the study.

2. Positive urine cotinine test, alcohol breath test, or drug test, unless for RI patients only, the subject uses any of these drugs as prescriptions that is approved by the PI.

3. Positive serology test results for HBsAg, HCV antibody, or HIV antigen and antibody at screening, or active infections.

4. History of significant allergic reactions (e.g., anaphylactic reaction, hypersensitivity, angioedema) to any drug, to mannitol, or to any excipient in the formulation of MT1002 for Injection.

5. Any acute illness within 14 days prior to the screening visit.

6. Clinically significant history of congenital or acquired bleeding disorders, thrombocytopenia or functional platelet defects, gastrointestinal disease with or without active ulceration, active cancer, vascular retinopathy, bronchiectasis, pulmonary cavitation, or pulmonary bleeding.

7. History of major bleeding, trauma, surgical procedure of any type, or vaginal delivery within 6 months prior to screening.

8. Personal or family history of clotting or coagulation disorder or abnormality, thrombovascular disease or any hematologic disorder involving platelets or clotting abnormalities or any condition requiring treatment with transfusions, anticoagulants or platelet inhibitors.

9. History of peptic ulcer, gastrointestinal bleeding (including hematemesis, melena, rectal bleeding) or bleeding from hemorrhoids within 6 months prior to screening.

10. History of easy bruising, excessive bleeding from an injury or after surgery or dental work, minor bleeding episodes such as epistaxis, rectal or hemorrhoidal bleeding (spots of blood on toilet paper), blood in urine or stool or history of black stools, or gingival bleeding within 3 months prior to screening.

11. Females with a history of dysfunctional uterine bleeding, including history of menorrhagia (heavy or long menstrual bleeding), metrorrhagia or polymenorrhea.

12. PT or aPTT > upper limit of normal at Screening or Day -1.

13. Donation of plasma within 7 days prior to dosing. Donation or loss of blood (excluding volume drawn at screening or menses) of 50 mL to 499 mL of blood within 30 days, or more than 499 mL within 56 days prior to the dosing.

14. Clinically significant abnormal laboratory test results (e.g. alanine aminotransferase (ALT), alkaline phosphatase (AP), aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT) or bilirubin) as judged by the Investigator or designee at Screening.

15. Clinically significant electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, or other currently prescribed medicinal products that lead to QT prolongation.

16. Administration of any blood product or anticoagulant within 1 month prior to screening.

17. Clinically significant ECG abnormalities (that could have jeopardized the subject's safety to participate in this study or a screening 12-lead ECG that demonstrated any one of the following: HR > 100 beats per minute (bpm), QRS > 120 msec, QTcF ≥450 ms in males or ≥470 ms in females, or PR > 220 msec, or vital signs abnormalities (systolic BP lower than 90 or over 140 mmHg, diastolic BP lower than 50 or over 90 mmHg, HR less than 50 or over 100 bpm, or RR less than 10 or over 22 bpm) at screening.

18. Unstable medical conditions or acute exacerbation of renal disease within 14 days of study drug administration.

19. Fluctuating or rapidly deteriorating RF as indicated by recent history or worsening of clinical and/or laboratory signs of RI as judged by the PI.

20. History, symptoms, or signs of severe hepatic impairment.

21. Subject who has renal disease secondary to malignancy.

22. Subjects with acute renal failure.

23. Subjects requiring dialysis.

24. Evidence of significantly impaired organ dysfunction or any clinically significant deviation from normal in physical examination, vital signs, electrocardiogram (ECG) or clinical laboratory determinations beyond what is consistent with the target population.

25. Subject is excluded at the discretion of the PI with consultation with the Medical Monitor if any of the following laboratory parameters at Screening and/or Baseline (Day -1) are above the followings: total bilirubin (TBL) > 1.5 × ULN, ALT and AST > 2 × ULN and ALP > 3 × ULN) at Screening or Day -1; hemoglobin < 8.5 g/dL.

26. Clinically significant ECG abnormalities or vital sign abnormalities (systolic BP lower than 90 or over 160 mmHg, diastolic BP lower than 50 or over 110 mmHg, or HR less than 45 or over 100 bpm) at screening. Any BP and HR values can be repeated at the discretion of the Investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Shaanxi Micot Pharmaceutical Technology Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Panax Clinical Research, LLC.

Miami, Florida, United States

Countries

United States

Other Identifiers

MT1002-I-C02

Identifier Type: -

Identifier Source: org_study_id